Societal Versus Healthcare Perspectives on the Cost Effectiveness of Ocrelizumab for Treatment of Primary Progressive Multiple Sclerosis in Aotearoa New Zealand
Treatment of PPMS with OCR is more cost effective from a societal than a healthcare perspective, therefore prioritisation of public funding of novel pharmaceuticals for MS and other resource intensive chronic health conditions will depend critically upon the study perspective.
Authors
- Carsten Schousboe (ORCID: https://orcid.org/0000-0002-0167-9444)
- John Mottershead (ORCID: https://orcid.org/0000-0001-5638-8786)
- Julie A. Campbell (ORCID: https://orcid.org/0000-0002-1820-6758)
- Richard J. Milne (ORCID: https://orcid.org/0000-0002-9410-1667)
Institutions
- University of Tasmania (AU)
- Statistics New Zealand (NZ)
- University of Otago (NZ)
Publication Details
- Journal
- PharmacoEconomics
- Published
- 2025-05-07
- DOI
- https://doi.org/10.1007/s40273-025-01486-z
- Citations
- 2
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 6.26
Funders
- F. Hoffmann-La Roche
- Multiple Sclerosis Australia
- University of Tasmania